ELAN - Elanco Animal Health Incorporated

NYSE - NYSE Delayed Price. Currency in USD
28.07
+0.54 (+1.96%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close27.53
Open27.74
Bid0.00 x 800
Ask0.00 x 1400
Day's Range27.60 - 28.37
52 Week Range25.51 - 37.61
Volume6,313,888
Avg. Volume3,947,296
Market Cap10.47B
Beta (3Y Monthly)N/A
PE Ratio (TTM)68.46
EPS (TTM)0.41
Earnings DateNov 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
Trade prices are not sourced from all markets
  • Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
    Zacks

    Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs

    Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.

  • GuruFocus.com

    Weekly CEO Buys Highlight

    Insiders invest in PVH, Coty, New Media Investment Group, Elanco Animal Health and Cott Continue reading...

  • Here's Why Elanco Animal Health Fell 21.1% in August
    Motley Fool

    Here's Why Elanco Animal Health Fell 21.1% in August

    The company's reliance on livestock animal products continues to weigh on operating results, so it announced a huge transaction to address that weakness.

  • A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
    TheStreet.com

    A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

    Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

  • Business Wire

    Elanco to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    Elanco Animal Health, Inc. (ELAN) will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, Sept. 11, 2019, in New York. Jeff Simmons, Elanco president and chief executive officer, will participate in a fireside chat at 8:45 a.m. Eastern Time. Investors and other interested parties will be able to access the live audio webcast of the presentation by visiting https://investor.elanco.com/investors/events-and-presentations/events-calendar/default.aspx.

  • GuruFocus.com

    Elanco Animal Health Inc (ELAN) President, CEO & Director Jeffrey N Simmons Bought $2 ...

    President, CEO & Director of Elanco Animal Health Inc (30-Year Financial, Insider Trades) Jeffrey N Simmons (insider trades) bought 75,750 shares of ELAN on 09/04/2019 at an average price of $26.55 a share. Continue reading...

  • InvestorPlace

    7 Stocks to Buy Down 10% in the Past Week

    Last week, President Donald Trump ordered United States companies to move their China-based operations elsewhere. The news sent the S&P 500 down by more than 2.5% in a single day of trading. The decline provided investors with some cheap stocks to buy. But which ones?A quick scan of stocks with market caps of $300 million or more that were down more than 10% over the past week brings up a total of 123 options, the largest being Dow (NYSE:DOW) at $31.3 billion and the smallest being Zynex (NASDAQ:ZYXI) at $300.9 million. InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn terms of sectors that were down, healthcare saw the most carnage with 36 stocks losing more than 10% last week, followed closely by basic materials at 35 and services at 21.Of the 123 stocks that lost more than 10% last week, 95 were small-caps with a market cap between $300 million and $2 billion; 24 were mid-caps between $2 billion and $10 billion, and just four had a market cap of more than $10 billion. I've recommended two of them in my group of seven cheap stocks to buy down more than 10% last week. Stocks to Buy: Dow (DOW)Source: JHVEPhoto / Shutterstock.com Over the past five days of trading through August 26, Dow stock lost 10.5%.Dow's stock has been under pressure due to two downgrades in a less than a month from Bank of America Merrill Lynch. The analysts expect lower demand of the company's chemical products to hurt future earnings. On July 26, Bank of America Merrill Lynch cut Dow's rating from "buy" to "neutral" suggesting its chemicals business was stuck in the mud with not much optimism for growth in the near term. This came one day after releasing second-quarter 2019 results that included a 14% decline in sales to $11.0 billion, a 3% decline in volumes and a 35% drop in operating earnings before interest and taxes to $1.1 billion. "In spite of challenging market conditions, our results reflect the benefits of Dow's streamlined and more focused portfolio, continued cost synergy savings and stranded cost removal. In the quarter, we faced margin compression in our intermediate products in both our core business and equity earnings," stated CEO Jim Fitterling. Then on Aug. 16, Bank of America Merrill Lynch downgraded DOW stock a second time to "underperform" from neutral. "We do continue to hold a favorable relative view on the long-term supply for caustic soda over polyethylene, but see these commodities driven in the near-term by sluggish demand," the firm said in a note to clients.Dow stock currently yields 6.8%. Get paid 70 cents a quarter to wait for these commodities to recover. Suzano (SUZ)Source: Shutterstock Over the five days of trading through Aug. 26, Suzano (NYSE:SUZ) stock lost 13.6%. What is Suzano? It's a Brazilian company that uses renewable resources to manufacture pulp and paper made from eucalyptus forests planted specifically for this purpose. It is the first pulp and paper producer in Brazil to use eucalyptus pulp in its products.Started in 1924 by Leon Feffer, the company originally was a reseller of domestic and imported paper for business cards, writing pads, etc. In 1930, it bought its first machine and began making its own paper. The rest is history. The Feffer family and related parties own approximately 46% of the company's shares. David Ferrer is currently the company's chairman of the board. It has 13 million hectares of tree plantations, the equivalent of 200 times the size of Manhattan. It has approximately a 40% share of the Brazilian paper market with more than 35,000 clients. Suzano is by far the biggest pulp producer in Brazil with more than 10.9 million tons capacity in 2018. Over the past four years, it's lowered its cash cost by 12% from $171 per ton to $150 per ton. In April, Suzano completed its $9.3 billion acquisition of Brazilian rival Fibria Celulose to become the world's largest cellulose producer. Why is Suzano's stock down?In the first half of 2019, there was a significant imbalance between pulp supply and demand leading to lower pulp prices. As a result, Suzano's net revenues in the second quarter fell by 20% over last year while its cash cost per ton increased by 11% reducing the division's profitability. * 10 Companies Using AI to Grow Suzano's paper business did much better in the second quarter with net revenues 15% higher and its adjusted earnings before interest, taxes, debt and amortization 45% higher. This compares to a 28% decline in adjusted EBITDA for its pulp segment. Long term, I like the company's prospects, but it first has to get through the current pricing weakness in the industry due to low global demand. Elanco Animal Health (ELAN)Source: Shutterstock Over the five days of trading through Aug. 26, Elanco Animal Health (NYSE:ELAN) stock lost 13.2%.The cause of last week's decline in Elanco's stock price had everything to do with the company's announcement that it would pay $7.6 billion to buy Bayer's (OTCMKTS:BAYRY) animal health unit. Elanco is paying $5.32 billion in cash and issuing approximately 68 million shares of its stock. As a result of the deal, which will double the size of Elanco's companion animal business, the company's debt will increase to five times its adjusted EBITDA. Not only that, but Elanco's share count will increase by 18%, seriously diluting existing shareholders. As a result of the additional debt, S&P and Fitch suggested that the deal could result in a credit rating downgrade from the rating agencies. Analysts believe that Bayer got top dollar for its animal health assets. While Elanco does plan to reduce its debt to adjusted EBITDA ratio to a multiple of three from five currently, the markets believe it might have overpaid for the assets. The merged company will be the second-largest animal health business in the world behind Zoetis (NYSE:ZTS). Although there is some question about Elanco's future growth, opportunities to buy quality assets like these don't come around every day. Long term, this deal should turn out to be a good one for Elanco shareholders. L Brands (LB)Source: JHVEPhoto / Shutterstock.com Over the five days of trading through Aug. 26, L Brands (NYSE:LB) stock lost 15.0%.As if things weren't going poorly enough for the owner of Victoria's Secret and Bath & Body Works, then-CEO and founder Les Wexner got his name all tangled up with the late financier Jeffrey Epstein, who pretended to be a talent scout for the lingerie retailer. Worth several billion dollars, investors started to wonder if the man who trusted such a sinister person with some of his finances could be trusted to turn around a struggling Victoria's Secret. Now, the company has been hit with a financial class-action suit that alleges the company and its executives, including Wexner, made misleading statements about its finances and ability to pay a high dividend despite an ongoing deterioration of its top and bottom line. Essentially, the suit claims that Wexner and company were way too optimistic about the business's overall financial condition in order to keep the stock price as high as possible. However, the worst blow to LB stock came Aug. 22 when it reported poor second-quarter 2019 sales that pushed L Brands stock to levels not seen since December 2009. That's a trifecta of doom that no stock can overcome. "L Brands still believes Victoria's Secret problems are product related, but we believe they are brand and competition related which means these problems are difficult to fix," Jefferies analyst Randal Konik said in a note to clients. "Bath & Body Works comps are slowing and margins are compressing which means the biz has peaked." * 10 Undervalued Stocks With Breakout Potential If not for the success of Bath & Body Works in the past two or three years, L Brands stock would likely be in single digits. Now that Bath & Body Works growth is slowing somewhat, the only investors who should consider investing are aggressive investors willing to accept a ton of risk. As a contrarian bet, I like it. After all, when investors get fearful, it's time to get greedy. Madison Square Garden (MSG)Source: Shutterstock Over the five days of trading through Aug. 26, Madison Square Garden (NYSE:MSG) stock lost 13.9%.The company that owns the New York Knicks and Rangers as well as the iconic Madison Square Garden among its many assets, announced Q4 2019 earnings Aug. 21 that was much worse than expected. The consensus estimate for the fourth quarter was a loss of $2.51 a share with revenue of $270.1 million. MSG actually delivered a loss of $3.08, 57 cents worse than expected, and revenue of $263.6 million; a miss on both the top and bottom line. The biggest investor concern seems to be the company's spherical entertainment venue that it's building in Las Vegas. At the same time it announced earnings, company president Andrew Lustgarten let investors know that the project would cost between $1.2 billion and $1.7 billion by the time it's completed. MSG Sphere, a partnership between the company and Las Vegas Sands (NYSE:LVS), is a state-of-the-art 18,000-seat arena that's expected to open in 2021. Unfortunately, investors see the T-Mobile (NASDAQ:TMUS) Arena just down the road that was built for $375 million in 2016, and can't help but think it's nothing but CEO and controlling shareholder James Dolan's ego project. While it might be Dolan's ego driving the project in Vegas, I'm sure the venue will become just as highly visited as the rest of MSG properties. Down 15% over the past year, the poor optics of MSG Sphere make the current correction a perfect time to buy MSG stock. CrowdStrike (CRWD)Source: Piotr Swat / Shutterstock.com Over the five days of trading through Aug. 26, CrowdStrike (NASDAQ:CRWD) stock lost 10.6%.The California-based cybersecurity company has only been a public company for a little over two months selling its stock to the public June 11 at $34 a share. On its first day of trading, it gained 70.6%; it's up 161.4% through August 27, making it one of the more successful IPOs in 2019, tech or otherwise. CrowdStrike delivers its second quarterly report as a public company on Sept. 5. If Q2 2020 results are as good as the results in its first quarter, investors can rest easy. On July 19, CrowdStrike reported Q1 2020 revenue of $96.1 million, $500,000 higher than the consensus estimate while its loss per share was 47 cents, on par with the analyst estimate. In the second quarter, CrowdStrike expects a loss of between 23 and 24 cents with revenue of at least $103 million. For all of 2020, it expects a loss of 70 to 72 cents with revenue of at least $430 million. At the time of its earnings release, CEO George Kurtz said that the company -- which provides endpoint network protection for companies whose employees access remote devices such as smartphones, laptops, tablets and other wireless devices -- is benefiting from the ongoing move by corporations to the cloud. To put the company's Q1 2019 report in perspective, overall revenues grew 103% year-over-year, subscription revenues grew 116% to $86.0 million, accounting for 89% of its sales and annual recurring revenue grew 114% to $364.6 million. * 10 Marijuana Stocks to Ride High on the Farm Bill Even its non-GAAP losses were 30% lower in the first quarter compared to a year earlier. While I try not to invest in money-losing businesses, the need for CrowdStrike's Falcon platform is real. In a couple of years, you will have forgotten that it once lost money. OrganiGram (OGI) Source: Shutterstock Over the five days of trading through Aug. 26, OrganiGram (NASDAQ:OGI) stock lost 10.6%.Cannabis stocks, in general, have taken it on the chin in recent days and weeks. The ETFMG Alternative Harvest ETF (NYSEARCA:MJ), which has total net assets of $1 billion and is the largest cannabis ETF listed in the U.S., has seen its shares lose 4.9% over those five days, 16.2% over the past month, and 28.3% over the past three months. So, the fact that the OrganiGram lost almost 11% in the past week should not come as a shock. OrganiGram is one of only four licensed producers that have supply agreements for all 10 Canadian provinces, it is ideally positioned to benefit from the growth in the Canadian cannabis market. On July 15, OrganiGram reported its Q3 2019 results. The company's net revenue was $24.8 million CAD, 621% higher than a year earlier. Its gross margin in the quarter was $12.3 million CAD, 647% higher than in the same quarter a year earlier. It had a surprise loss of $10.2 million CAD in the third quarter, down from a profit of $2.8 million CAD a year earlier. But CEO Greg Engel is very excited about the company's future."We are very excited for fiscal 2020 which should build upon an already successful 2019," the company stated in its press release. "By the first half of fiscal 2020, we expect to benefit from record harvests of high-quality indoor-grown dried flower, the sale of a variety of vape pen products as well as our initial edible product forms."The company's state-of-the-art three-level indoor cultivation facility's expansion in New Brunswick will be completed by the end of 2019. At that time, it will have 113,000 kilograms of cannabis production capacity to meet the needs of all 10 provinces. As for edibles and derivative products, it expects to complete the 56,000 square-foot addition to its Moncton facility by the end of October at a cost of $48 million CAD. It is well-positioned to benefit from Canadian legalization in December. OrganiGram's chocolate products alone should bring it significant revenue in 2020. This is one of the cannabis companies I haven't paid much attention to but you shouldn't repeat my mistake. The stock's correction makes it an excellent time to take a closer look.I know I will. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Industry Dividend Stocks for Growth and Income * 7 Stocks the Insiders Are Buying on Sale * 7 of the Worst Stocks on Wall Street The post 7 Stocks to Buy Down 10% in the Past Week appeared first on InvestorPlace.

  • Benzinga

    The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics ...

  • Benzinga

    Bank Of America Downgrades Elanco Animal Health, Says Too Much Uncertainty Around Bayer Deal

    Last week, Elanco Animal Health Incorporated (NYSE: ELAN) announced plans to acquire Bayer’s (OTC: BAYRY) Animal Health business for $7.6 billion. The purchase price of Elanco Animal Health’s deal to acquire Bayer’s Animal Health business is much lower than what some reports had speculated, Ryskin said in the note.

  • TheStreet.com

    Elanco Animal Health Slips on BoFA/Merrill Lynch Downgrade to Neutral

    Elanco Animal Health falls Monday after Bank of America/Merrill Lynch downgrades the animal health company to neutral from buy.

  • Editor's briefing: The biggest development story you may have missed, and women you need to know
    American City Business Journals

    Editor's briefing: The biggest development story you may have missed, and women you need to know

    Here are two topics you need to pay attention to. One is a deal that involves the fate of some 650 area jobs in a high-priority industry. The other is the stories of our 2019 Women Who Mean Business honorees that I guarantee will impress and inspire you.

  • Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco
    Zacks

    Bayer Inks $7.6B Deal to Divest Animal Health Unit to Elanco

    Bayer (BAYRY) inks deal with Elanco to divest its animal health business for $7.6 billion.

  • Bayer Sells Animal Health Division to Elanco: Now What?
    Zacks

    Bayer Sells Animal Health Division to Elanco: Now What?

    On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.

  • Motley Fool

    What Happened in the Stock Market Today

    Home Depot rose despite reporting mixed results, and Elanco announced a deal with Bayer for its animal health business.

  • Pharma Stock Dives After Unveiling $7.6 Billion Animal-Health Merger
    Investor's Business Daily

    Pharma Stock Dives After Unveiling $7.6 Billion Animal-Health Merger

    Elanco Animal Health stock toppled Tuesday after announcing its $7.6 billion takeover of Bayer's animal health segment. Elanco stock plunged almost 9% at the close of the stock market.

  • Bayer to sell animal health unit for $7.6B
    American City Business Journals

    Bayer to sell animal health unit for $7.6B

    Bayer AG has agreed to sell its animal health business to Indiana-based Elanco Animal Health Inc. in a cash and stock deal worth $7.6 billion, the latest in the German company's divestitures as it faces mounting legal bills related to its Roundup herbicide.

  • $7.6B purchase of Bayer Animal Health makes Elanco a big dog in KC
    American City Business Journals

    $7.6B purchase of Bayer Animal Health makes Elanco a big dog in KC

    Bayer AG, which has a large presence in the Kansas City area, will sell its animal health business to Elanco Animal Health Inc. in a transaction valued at $7.6 billion.

  • Elanco to become No.2 in animal health with $7.6 billion Bayer deal
    Reuters

    Elanco to become No.2 in animal health with $7.6 billion Bayer deal

    The deal is the latest in the fast-growing animal health market, which has recently seen Elanco floated by Eli Lilly and Co and rival U.S. drugmaker Pfizer also spinning off its veterinary medicine business. It also adds to the list of assets sold by Bayer, as the German company looks to slash debt from its $63 billion takeover of seed maker Monsanto last year and as it braces for a potential settlement of lawsuits over an alleged cancer-causing effect of weedkiller Roundup. The two companies said Bayer would receive $5.3 billion in cash and $2.3 billion worth of Elanco stock based on a price of $33.60 per share, the 30-day average price as of Aug. 6.

  • Companies to Watch: Baidu posts earnings beat, Southwest cuts down on routes, new details on Disney+
    Yahoo Finance

    Companies to Watch: Baidu posts earnings beat, Southwest cuts down on routes, new details on Disney+

    Baidu, Southwest Airlines, U.S. Steel, Elanco and Disney are the companies to watch.

  • Benzinga

    Elanco To Acquire Bayer's Animal Health Business For $7.6B

    Elanco Animal Health Inc (NYSE: ELAN ) shares were trading lower Tuesday after the company announced it would acquire Bayer AG (OTC: BAYRY )'s animal health business for $5.32 billion in cash and $2.28 ...

  • Elanco to buy Bayer's animal health unit for $7.6 billion
    Reuters

    Elanco to buy Bayer's animal health unit for $7.6 billion

    Elanco Animal Health Inc said on Tuesday it would buy Bayer AG's animal health unit in a cash and stock deal valued at $7.6 billion, a move that would create the second largest animal health business and expand Elanco's reach in the pet e-commerce space. The animal health market has seen Pfizer Inc and Eli Lilly and Co, successfully floating their veterinary medicine units on the stock market as independent entities.

  • MarketWatch

    Elanco buying Bayer's animal health business for $7.6 billion

    Elanco Animal Health said it's buying Bayer's animal health business for $7.6 billion. Elanco said it will pay $5.32 billion in cash and $2.28 billion in stock. Elanco said it intends to fund the cash consideration through a combination of new debt and equity. At close, Elanco expects its gross debt to adjusted EBITDA leverage ratio to be 5x.

  • Business Wire

    Elanco Announces Agreement to Acquire Bayer’s Animal Health Business

    Elanco Animal Health Incorporated (ELAN) today announced it has entered into an agreement with Bayer AG (BAYN) to acquire its animal health business in a transaction valued at US$7.6 billion. The transaction, which is subject to regulatory approval and other customary closing conditions, creates the second largest animal health leader while strengthening and accelerating the company’s proven Innovation, Portfolio and Productivity (IPP) strategy.

  • TheStreet.com

    [video]Elanco to Buy Bayer's Animal Health Business for $7.6 Billion

    Elanco says the deal, which is subject to approval from regulators, would double the size of its companion animal business.